CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone.
OBJECTIVE
Chemokines may play a role in the pathogenesis of multiple sclerosis (MS), facilitating the trafficking of immune cells across the blood-brain barrier. Interferon-inducible T-cell alpha-chemoattractant (CXCL11) recruits activated Th1 cells to sites of inflammation. In this study, we wanted to estimate the levels of CXCL11 chemokine and interleukin-18 (IL-18), a proinflammatory cytokine, in sera of relapsing-remitting MS (RRMS) patients, both before and after methylprednisolone (MP) treatment, and to compare the results with those in the control group.


METHODS
Serum CXCL11 and IL-18 concentrations were measured by the ELISA method in 30 RRMS patients during relapse both before and after MP treatment, and in 20 healthy blood donors.


RESULTS
We found significantly increased CXCL11 and IL-18 serum levels in RRMS patients as compared with controls. Additionally, no influence of MP therapy on the serum levels of CXCL11 and IL-18 was observed.


CONCLUSIONS
We suggest that CXCR3 receptor ligand, CXCL11, may be involved in MS pathogenesis.
Szczuciński
Adam
A
Department of Clinical Neuroimmunology, University of Medical Sciences, Poznań, Poland. adamszczucinski@poczta.onet.pl
Kalinowska
Alicja
A
Losy
Jacek
J
D000328:Adult; D054371:Chemokine CXCL11 / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D020382:Interleukin-18 / Q000097:blood*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood* / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D018709:Statistics, Nonparametric